<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00615940</url>
  </required_header>
  <id_info>
    <org_study_id>WX/60-006</org_study_id>
    <nct_id>NCT00615940</nct_id>
  </id_info>
  <brief_title>Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer</brief_title>
  <official_title>A Phase 2, Two-arm, Double-blind, Multi-center, Randomized Study of the Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wilex</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Medical Research and Materiel Command</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Wilex</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, double-blind, placebo controlled phase II trial is studying how well
      capecitabine works when given in combination with WX-671 or when given alone in treating
      patients receiving first-line therapy for her2negative metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in terms of progression-free survival (PFS)</measure>
    <time_frame>disease staging with CT/MRI/bone scans at regular intervals</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary endpoints are objective response rate (ORR), overall survival, safety and pharmacokinetics.</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">132</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with WX-671 once daily by mouth, Days 1-21 inclusive.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine, 1000 mg/m2, twice daily by mouth, on Days 1 to 14, followed by a 7 day rest in each 21 day cycle given in combination with placebo once daily by mouth, Days 1-21 inclusive.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>WX-671</intervention_name>
    <description>capsules taken per os once daily until progression or toxicity</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>capsule taken per os once daily until progression or toxicity</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females aged ≥ 18 years

          -  Patients appropriate for palliative first-line, mono chemotherapy with capecitabine

          -  Histological or cytological confirmed, non-inflammatory metastatic breast cancer

          -  Availability of paraffin-embedded tumor tissue from the primary resection or biopsy of
             a metastatic lesion.

          -  HER2-negative breast cancer

          -  Complete staging within 2 weeks prior to randomization (4 weeks for bone scan).

          -  Radiologically confirmed disease

          -  ECOG performance status of ≤ 2

          -  Ability to understand and willingness to voluntarily sign and date a written informed
             consent form before screening

          -  Negative pregnancy test (urine or serum) within 3 days before first study drug for
             women of childbearing potential. Use of effective contraception during the study and
             for 3 months after stopping study drug treatment.

          -  Normal organ and marrow function as defined by laboratory parameters (obtained within
             the screening period) within the following limits:

               -  neutrophils &gt;= 1.5 x 109/L;

               -  platelets &gt;= 100 x 109/L;

               -  hemoglobin &gt;= 9.0 g/dL (5.6 mmol/L).

               -  total bilirubin &lt;= 1.5 x upper limit of normal (ULN);

               -  aspartate aminotransferase (AST)/ALT &lt;= 2.5 x ULN (&lt; 5.0 x ULN for patients with
                  liver metastases);

               -  serum creatinine &lt;= 2 x ULN, or calculated creatinine clearance &gt;45 mL/min
                  according to Cockroft and Gault formula).

        Exclusion Criteria:

          -  Endocrine therapy completed within 2 weeks before the start of treatment (i.e.
             previous hormone therapy is allowed provided that there is a washout period of 2
             weeks).

          -  Prior chemotherapy or biologic therapy for metastatic disease.

          -  Major surgery within 4 weeks prior to the start of treatment.

          -  Other anti-cancer treatment (e.g. hormones) within 2 weeks before the start of
             treatment.

          -  Treatment within 12 months with adjuvant 5-FU containing chemotherapy (regarded as
             indicating 5-FU resistance) and/or prior capecitabine therapy.

          -  Radiation therapy. Palliative radiation of stable, non-target lesions more than 2
             weeks before the start of treatment is allowed, provided patients have recovered from
             the radiation side-effects.

          -  History of or radiological evidence of brain metastasis including previously treated,
             resected or asymptomatic brain lesions or leptomeningeal involvement.

          -  Active seizure disorder or history of cerebrovascular accident (CVA) or transient
             ischemic (TI) attack within the past 12 months.

          -  History of other malignancy within the last 3 years except for surgically cured
             non-melanoma skin cancer or cervical carcinoma in situ.

          -  Active cardiac disease e.g. unstable angina, congestive heart failure, myocardial
             infarction (MI) within the preceding 6 months.

          -  Any medical condition prohibiting standard imaging procedures

          -  Pregnant or breast-feeding.

          -  Any unrelated illness, e.g. active infection requiring parenteral antibiotics,
             inflammation, medical condition or laboratory abnormalities, which in the judgment of
             the investigator might significantly affect patients' study participation.

          -  Any surgical or medical condition that might significantly alter the absorption,
             distribution, metabolism or excretion of either study drug.

          -  Known hepatitis B/C or HIV (human immunodeficiency virus) infection.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori Goldstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Medical Oncology, Division of Medical Science, Fox Chase Cancer Center, 7701 Burholme Avenue, Philadelphia, Pennsylvania 19111, USA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nadia Harbeck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Uniklinik Köln</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montefiore Medical Center Weiler Division Department</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitys Hospital Case Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Klina, Oncology Department</name>
      <address>
        <city>Brasschaat</city>
        <zip>2930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet Oncologie Médicale</name>
      <address>
        <city>Bruxelles</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liège, Domaine Universitaire de Sart-Tilman, Oncology Department</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irmandade de Misericórdia da Santa Casa de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <zip>9005</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional do Câncer - INCA</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>20560</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Brasileiro de Controle do Câncer - IBCC</name>
      <address>
        <city>São Paulo</city>
        <zip>03102</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Dr. Brudler, Dr. Heinrich, Dr. Bangerter</name>
      <address>
        <city>Augsburg</city>
        <zip>86150</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Uniklinik Köln</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Innere Klinik und Poliklinik (Tumorforschung)</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Frankfurt, Zentrum der Frauenheilkunde und Geburtshilfe</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Martin-Luther-Universität Halle-Wittenberg, Poliklinik Gynäkologie</name>
      <address>
        <city>Halle/Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Technical University</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethesda KH</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41061</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Davidof Center, Rabin Medical Center, Department of Oncology</name>
      <address>
        <city>Petah Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaplan Medical Center, Department of Oncolocy</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center, Department of Oncology</name>
      <address>
        <city>Tel Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofeh medical center, Department of Oncology</name>
      <address>
        <city>Zerifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Ukraine</country>
  </removed_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 1, 2008</study_first_submitted>
  <study_first_submitted_qc>February 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 14, 2008</study_first_posted>
  <disposition_first_submitted>January 28, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>January 28, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 28, 2014</disposition_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2negative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

